Michael Little, PhD — ADVISOR
During the last year, Michael has been Senior Vice President of R&D for Natera and President of Futura Partners, a healthcare advisory firm. At Futura, he advises clients from the pharma, life sciences and diagnostics industries in areas including diagnostics, companion diagnostics, and technical leadership development. He is a member of the Board of Directors of a Cambridge MA private startup company focused in personalized medicine (pulmonology), and has been a consultant to the investors and Board of Directors of another personalized medicine company in the breast cancer field.
Previously, he was Vice President and Global Head at Novartis. For the 1st 2 years, he oversaw R&D, medical affairs, and regulatory affairs for Novartis (Chiron) Diagnostics in Emeryville CA. When Novartis chose to build a new business unit focused on molecular and companion diagnostics within Pharma, he was selected to be one of the founding members to build a Diagnostics Development organization and processes from scratch in Cambridge MA. Over a period of 5 years he had responsibility for nearly 30 programs spanning Novartis’ entire oncology and general medicine portfolio.
Prior to Novartis, he was the Chief Operating Officer of Adlyfe, a venture-funded company in Rockville, focused on misfolded protein diagnostics. During this time, he had accountability for both finance raising and R&D programs.
Michael spent 16 years with Becton Dickinson, where he began as an R&D scientist developing a proprietary nucleic acid amplification technology, Strand Displacement Amplification (SDA), and would ultimately run the business resulting from this initial research work. He assumed responsibility for and ran the R&D programs for BDs flagship SDA platforms, the BDProbeTecET and BDViper. After successfully completing the development in record time and gaining FDA clearance for the very 1st real-time DNA amplification system (beating the nearest competitor by 1 year), he assumed the leadership of the resulting molecular business. This business grew from 0-$100M within 5 years and achieved an aggregate of over $1B in revenue since.
His earlier career in biotech included a brief tenure at BioRad where he developed products for life science researchers, and at Baxter Dade, where he developed clinical immunoassay and coagulation products. He received his PhD in Microbiology from the University of Florida and completed post-doctoral training at the University of Arizona in Tucson.
JURGEN SCHMITT, PhD — ADVISOR
Dr. Jurgen Schmitt was appointed as a scientific advisor at Todos in October 2016. Dr. Schmitt brings over 20 years of experience in FT-IR and Raman spectroscopy research in microbiological and biomedical applications, as well as R&D and industrial applications in the diverse fields of Biotechnology, Medicine and Pharmaceutics. Since 2000, he founded and acted as CEO of Synthon GmbH, a Company dedicated to the Development of Spectroscopic Applications in Medicine, Biotechnology and Pharmaceutical Research. Synthon is based in Heidelberg, Germany. Prior to that, Dr. Schmitt held scientific and academic positions at the University of Duisburg, Germany, Department of Aquatic Microbiology; University of Stuttgart, Institute for Water Quality and Water Chemistry; and Oak Ridge National Laboratory, US.
WALTER CARNEY, PHD — ADVISOR
Dr. Carney received his PhD in Medical Microbiology and Infectious Diseases from Thomas Jefferson Medical School in Philadelphia, PA in 1978. Over the past two years, Dr. Carney has founded and been the CEO of Walt Carney Biomarkers Consulting. Prior to establishing his own consulting firm, Dr. Carney had a distinguished career at Oncogene Science. Dr. Carney was employed at Oncogene for over 23 years in a variety of positions. These positions include Chief Scientific Officer, Executive Vice President and President. Dr. Carney serves on the Advisory Board of Sigmet Laboratories and Vermillion. Dr. Carney has also garnered many awards including the Forever Fellowship, NIH Fellow and the Otto Bayer Science award. Dr. Carney is a respected member of the American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), American Association for the Advancement of Clinical Science (AAAS) as well as the American Association for Clinical Chemistry (AACC).